Systemic therapies-based combination treatments have been developed rapidly in patients with advanced hepatocellular carcinoma (HCC). However, there are still a few patients not applicable to any recommended therapies, making it considerable to try new therapeutic options. Among them, anlotinib, a new oral tyrosine kinase inhibitor, is being widely used for many advanced malignancies. We present the first case of the antitumor effect of complete remission by anlotinib combined with an anti-programmed cell death protein 1 antibody, sintilimab, in a patient with advanced HCC. In April 2020, a 51-year-old male patient was diagnosed with large HCC and underwent hepatectomy with R0 resection. Two months later, he was admitted to our hospital because of a tumor relapse with multiple liver and lung metastases. After the failure of comprehensive treatment containing sorafenib, camrelizumab and transhepatic arterial chemotherapy and embolization, 2 months after tumor relapse, the patient started to receive anlotinib and sintilimab. The multiple tumor nodules were remarkable repressed both in the liver and lung. Six months after anlotinib plus sintilimab treatment, there were no residual tumors, and the alpha-fetoprotein level was decreased from 2310.9 mg/L to normal. Also, the patient continued to receive anlotinib to date. In subsequent follow-up visits until now, there was no sign of recurrence found on imaging. Anlotinib is a promising alternative for patients insensitive to the first-line targeted drugs. More clinical studies should be conducted to further broaden the clinical indications of anlotinib and immunotherapy in patients with HCC.

中文翻译：

---

安罗替尼联合信迪利单抗在晚期肝细胞癌患者中取得完全缓解的抗肿瘤效果：病例报告。

基于全身治疗的联合治疗在晚期肝细胞癌（HCC）患者中得到了迅速发展。然而，仍有少数患者不适合任何推荐的治疗方法，因此尝试新的治疗方案非常重要。其中，安罗替尼作为一种新型口服酪氨酸激酶抑制剂，正在广泛用于多种晚期恶性肿瘤的治疗。我们提出了首例安罗替尼联合抗程序性细胞死亡蛋白 1 抗体信迪利单抗对晚期 HCC 患者产生完全缓解的抗肿瘤效果。2020年4月，一名51岁男性患者被诊断出患有大肝癌，并接受了R0切除的肝切除术。两个月后，因肿瘤复发伴肝、肺多发转移入院。索拉非尼、卡瑞利珠单抗和肝动脉化疗栓塞等综合治疗失败后，肿瘤复发2个月后，患者开始接受安罗替尼和信迪利单抗治疗。肝脏和肺部的多个肿瘤结节均受到显着抑制。安罗替尼联合信迪利单抗治疗六个月后，无残留肿瘤，甲胎蛋白水平从2310.9 mg/L降至正常。此外，患者迄今为止仍继续接受安罗替尼治疗。至今为止的后续随访中，影像学未发现复发迹象。对于对一线靶向药物不敏感的患者来说，安罗替尼是一种有前景的替代药物。应开展更多临床研究，进一步拓宽安罗替尼和免疫治疗治疗 HCC 患者的临床适应症。